Furthermore, reduced serum VIP levels have been described in different inflammatory/autoimmune diseases, emerging as a potential prognostic biomarker in patients with early arthritis15,16 and early spondyloarthritis (SpA)17. The gene discussed is VIP; the disease is autoimmune disease.